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Available online 31 August 2015AbstractGliptins represent a dipeptidyl peptidase-4 inhibitors that improve beta cell health and suppress glucagon, leading to improved
post-prandial and fasting hyperglycemia used for the treatment of type 2 diabetes mellitus. A simple and quick approach of stability
indicating RP-HPLC technique was developed for the determination of Metformin, (Met), Saxagliptin (Saxa) and Sitagliptin (Sita)
in bulk and pharmaceutical dosage forms. This projected methodology is apt for the multicomponent estimation of 2 totally
different commercially existing combinations in pharmaceutical market used for the treatment of type II diabetes mellitus viz.
Sitagliptin and metformin, saxagliptin and metformin in 8 min. A chromatographic separation of the three drugs was attained with a
Inertsil C18 (4.6  250 mm, 5 mm) analytical column using a buffer potassium dihydrogen phosphate adjusted pH 4 with ortho-
phosphoric acid: methanol:acetonitrile (70:10:20%v/v) in isocratic mode at a flow rate of mL/min, column at ambient temperature
and detection of each 3 drugs were monitored at 215 nm using a DAD detector. These established techniques were subjected for
forced degradation studies in different stress conditions. This suggested methodology was found to be specific and stability
indicating as no interfering peaks of degradation compounds in forced degradation study and excipients was noticed. The
Robustness study and percentage of the assay of the formulations was established within the limit of ICH guidelines.
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Metformin chemically N, N-diethyl imido dicarbo-
nimidic diamide hydrochloride belongs to the bi-
guanide class of anti-diabetic drug [1]. Sitagliptin
phosphate monohydrate chemically [2], (3R)-3-amino-
1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-
a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-n behalf of University of Kerbala. This is an open access article under
4.0/).
Table 1
Confirmed chromatographic conditions.
1 Equipment High performance liquid chromatography
equipped with auto sampler and DAD
or UV detector
2 Column Inertsil C18 (4.6  250 mm, 5 mm)
3 Flow rate 1.0 ml per min
4 Wavelength 215 nm
5 Injection volume 20 mL
6 Column temperature Ambient
7 Runtime 10 min
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agliptin chemically [3], (1S,3S,5S)-2-[(2S)-2-Amino-
2-(3hydroxy tricycle [3.3.1.13,7]dec-1-yl) acetyl]-2-
azabicyclo[3.1.0] hexane-3-carbonitrile.Saxagliptin is
an orally active hypoglycemic of the new dipeptidyl
peptidase-4 (DPP-4) inhibitor class of drugs that was
being introduced after Sitagliptin. Moreover Sitagliptin
and Saxagiptin are used for the improvement of gly-
cemic control in patients with type II diabetes mellitus
as monotherapy or combination therapy with metfor-
min or a peroxisome proliferator activated receptor
gamma (PPAR) agonist (e.g., thiazolidinediones) when
the single agent does not provide adequate glycemic
control. Rising demand of DPP-4 class inhibitor drug
in pharmaceutical market, it is required to develop a
new cost-effective, fast and precise analytical LC
technique for the estimation of drug in bulk as well as
pharmaceutical dosage forms. Literature review indi-
cate that few simultaneous LC methods have been re-
ported for analysis of DPP-4 inhibitor class drugs such
as Sitagliptin with Metformin [4e6] and for Metformin
with Saxagliptin [7,8]without stability study but there
is not at all any multicomponent techniques were
developed or reported for the estimation on above
mentioned drugs in bulk or pharmaceutical dosage
form. Additionally, existing simultaneous methods
were less cost-effective and more time consuming not
fit for the multicomponent estimation. Hence the main
goal of the project is to develop single cost-effective
LC method for the analysis of metformin, saxagliptin
and sitagliptin that wasn't developed so far, hence it
may apply with success for the estimation of 2 totally
different pharmaceutical combos.
2. Experimental
2.1. Chemicals and reagents
Sitagliptin, Saxagliptin and Metformin standards
were obtained from Mylan laboratories limited,
Hyderabad, India. Methanol (HPLC-grade) was ob-
tained from Merck Fine Chemicals (Mumbai, India).
Sodium hydroxide (NaOH), hydrogen peroxide
(H2O2) and hydrochloric acid (HCl), were from S D
fine Chemicals, Alpha Pharma limited and Finar
chemicals respectively. The 0.45-mm pump nylon fil-
ter was from Advanced Microdevices (Ambala Cantt,
India). Istamet, Janumet, Kombiglyze were purchased
from the native pharmaceutical market. Double-
distilled water was used during the experiment.
Further chemicals were used by analytical or HPLC-
grade.2.2. HPLC instrumental condition
Instrument used in the study was Shimadzu-LC
equipped with Auto Sampler, DAD or UV detector
and Empower software. A chromatographic separation
of the three drugs was achieved with a Inertsil C18
(4.6  250 mm, 5 mm) analytical column using buffer
potassium dihydrogen phosphate adjusted pH 4 with
orthophosphoric acid: methanol:acetonitrile
(70:10:20%v/v) in isocratic mode at a flow rate of
1 mL/min, column at ambient temperature and detec-
tion of all the drugs were monitored at 215 nm using a
DAD detector. All the solvents were filtered through
0.45-mm nylon filter, and degassed in an ultrasonic bath
previous to use. Measurements were carried out by
using injection volume 20 mL and detection at 215 nm.
For analysis of forced degradation analysis of samples,
the PDA detector was used in scan mode with a scan
range of 200e400 nm. The peak uniformity was
expressed in terms of peak purity and was obtained
spectral analysis report using previously mentioned
software. Analytical method was optimized by using
pure analytical standards (Table 1).
2.3. Preparation of standard solution
Accurately weigh and transfer 10 mg of the Met,
Saxa and Sita working standard into a 10 mL, 100 mL
and 10 mL clean, dry volumetric flasks add diluent and
sonicate to dissolve it completely and make the volume
up to the mark with the same solvent (Stock solution).
Further pipette 2.0 mL of Met, 0.2 mL of Saxa and
0.2 mL Sita of the above stock solution into a 10 mL
volumetric flask and dilute up to the mark with diluent.
2.4. Analysis of formulations
20 tablets of 3 totally different brands (Istamet,
Janumet, Kombiglyze) were taken and their average
weight was calculated. The tablets were crumpled to a
fine powder, dose equivalent to 10 mg equivalent
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10 mL clean, dry volumetric flask, add diluent and
sonicate to dissolve it completely and make the volume
up to the mark with the same solvent (Stock solution).
Further pipette 2 mL of the above stock solution into a
10 mL volumetric flask and dilute up to the mark with
diluent. Inject 20 mL of the standard, sample into the
chromatography system and measure the areas for the
Met, Saxa and Sita peaks and calculate the percentage
of the assay of the formulations.
3. Validation of chromatographic method
3.1. Accuracy or recovery
Accuracy is represented and determined by recov-
ery experiments. In this process, it was tested at three
different levels that were 50,100 and 150% and
analyzing Chromatogram.
3.2. Specificity
To assess the strategy specificity, working placebo
solution (blank) in the absences of the Met, Saxa, Sita
and standard solution having a concentration of 200, 2,
20 mg/mL of the Met, Saxa, Sita respectively as well as
formulations were introduced into the LC system.
3.3. Precision
Precision and intermediate precision/ruggedness of
the analytical method were established for both system
and method/procedure by using concentration of 200,
2, 20 mg/mL of Met, Saxa and Sita by six replicate
injections. Method precisions were achieved by indi-
vidual sample preparations each of the three drugs
from the same batch.
3.4. Linearity
It was demonstrated by preparing and analyzing the
standard preparation at 5 totally different concentra-
tions. The represented methodology shows outstanding
linearity over a range of 100, 150, 200, 250, 300 mg/
mL for Met, 1, 1.5, 2, 2.5, 3.0 for Saxa and 10, 15, 20,
25, 30 mg/mL for Sita.
3.5. Limit of detection (LOD)
LOD based on signal to noise ratio. It is achieved by
comparing measured signals from samples with known
low concentrations of analyte with those of blanksamples and establishing the minimum concentration
so that analyst can be reliably detected.
Acceptance benchmarks: S/N ratio value shall be 3
for LOD solution
Calculation of S/N ratio: (metformin)
Average baseline noise obtained from blank: 46 mV.
The signal got from LOD solution: 136 mV.
S/N ¼ 136/46 ¼ 2.96 (conc-0.03 mg/mL)
Calculation of S/N ratio: (Saxagliptin)
Average baseline noise obtained from blank:
46 mV.
The signal got from LOD solution: 131 mV.
S/N ¼ 131/46 ¼ 2.85 (conc-0.0017 mg/mL)
Calculation of S/N ratio: (sitagliptin)
Average baseline noise obtained from blank: 46 mV.
The signal got from LOD solution: 133 mV.
S/N ¼ 133/46 ¼ 2.89(conc-0.025 mg/mL)
3.6. Limit of quantification (LOQ)
LOQ based on signal to noise ratio. It is achieved by
comparing measured signals from samples with known
low concentrations of analyte with those of blank
samples and establishing the minimum concentration
so that analyst can be reliably quantified.
Calculation of S/N ratio: (metformin)
Average baseline noise obtained from blank:
46 mV.
The signal got from LOQ solution: 458 mV.
S/N ¼ 458/46 ¼ 9.96(conc-0.068 mg/mL)
Calculation of S/N ratio: (saxagliptin)
Average baseline noise obtained from blank:
46 mV.
The signal got from LOQ solution: 461 mV.
S/N ¼ 461/46 ¼ 10.02(conc-0.013 mg/mL)
Calculation of S/N ratio: (sitagliptin)
Average baseline noise obtained from blank:
46 mV.
The signal got from LOQ solution: 455 mV.
S/N ¼ 455/46 ¼ 9.89(conc-0.084 mg/mL)
Acceptance benchmarks: S/N ratio value shall be 10
for LOQ solution.3.7. System suitability study
System suitability tests were carried out on a freshly
prepared standard solution of the Met, Saxa and Sita to
scrutinize the various optimized parameters. Such as
plate count, resolution and tailing factor.
42 S.N. Konari, J.T. Jacob / Karbala International Journal of Modern Science 1 (2015) 39e483.8. Robustness study
The robustness of the method was studied by negli-
gible variations in the technique such as altering the
wavelength of detection, flow rate, column temperature
and changes in composition of the mobile phase.
4. Degradation studies
The International Conference on Harmonization
(ICH) guideline entitled stability testing of new drug
substances and products requires that stress testing be
carried out to elucidate the inherent stability charac-
teristics of the active substance. The goal of this work
was to carry out the stress degradation studies on the
Met, Saxa & Sita using the proposed method.
4.1. Standard solution preparation
Standard solution of Met, Saxa & Sita were prepared
to get concentration of 200, 2, 20 mg/mL respectively.
4.2. Hydrolytic degradation in acidic condition
From above stock solution, pipette out 2.0 mL,
0.2 mL and 0.2 mL of the Met, Saxa and Sita in 10 mL
of volumetric flask and added 1 mL of 0.1 N HCl to it.
Then, the volumetric flask was kept in a water bath at
60e70 C for 1 h and neutralized with 0.1 N NaOH.
Finally, make up to 10 mL with diluents to get con-
centration of 200, 2, 20 mg/mL of the Met, Saxa and
Sita respectively. Cool the solution to room tempera-
ture. Filter the solution with 0.45 micron syringe filters
and place in vials of the HPLC system.
4.3. Hydrolytic degradation in alkaline condition
From above stock solution, pipette out 2.0 mL,
0.2 mL and 0.2 mL of the Met, Saxa and Sita in 10 mL
of volumetric flask and added 1 mL of 0.1 N NaOH to
it. Then, the volumetric flask was kept in a water bath
at 60 70 C for 1 h and neutralized with 0.1 N HCl.
Finally, make up to 10 ml with diluents to get con-
centration of 200, 2, 20 mg/mL of the Met, Saxa & Sita
respectively. Cool the solution to room temperature.
Filter the solution with 0.45 micron syringe filters and
place in vials of the HPLC system.
4.4. Thermally induced degradation
From above stock solution, pipette out 2.0 mL,
0.2 mL and 0.2 mL of the Met, Saxa and Sita in 10 mLof volumetric flask and added 3 mL of diluent to it.
Then, volumetric flask was kept in hot air oven at
60e70 C for 1 h. Finally, make up to 10 mL with
diluents to get concentration of 200, 2, 20 mg/mL of the
Met, Saxa & Sita respectively. Cool the solution to
room temperature. Filter the solution with 0.45 micron
syringe. Filters and place in vials of the HPLC system.
4.5. Oxidative degradation
From above stock solution, pipette out
2.0 mL,0.2 mL and 0.2 mL of the Met, Saxa & Sita in
10 mL of volumetric flask and added 1 mL of 3% w/v
Hydrogen peroxide to it. Then, the volumetric flask
was made up to 10 mL with diluents to get concen-
tration of 200, 2, 20 mg/mL of the Met, Saxa and Sita
respectively and kept aside for 30 min. Filter the so-
lution with 0.45 micron syringe filters and place in
vials of the HPLC system respectively.
4.6. Photo degradation
From above stock solution, pipette out 2.0 mL,
0.2 mL and 0.2 mL of the Met, Saxa and Sita in 10 mL
volumetric flask. Then, the samples were transferred
into a petri dish and kept in Photostability chamber
200 Wh/m2 in UV light and 1.2 million l  h in visible
light for 5 h. Finally, volumetric flask was made up to
10 mL with diluents to get concentration of 200, 2,
20 mg/mL of the Met, Saxa and Sita respectively. Cool
the solution to room temperature. Filter the solution
with 0.45 micron syringe and place in vials of the
HPLC system.
5. Results and discussion
5.1. Optimization of chromatographic techniques
Throughout the method development [9e14],
numerous trails have been carried out to confirm
optimized chromatographies condition. At first binary
solvents as phosphate buffer pH 3.0: methanol
(45:55%v/v), phosphate buffer pH 3.0: methanol
(60:40%v/v), phosphate buffer pH 4.0: acetonitrile
(60:40%v/v), phosphate buffer pH 3.0: acetonitrile
(40:60%v/v) at 208 nm were attempted however did
not get clear conclusion due splitting of peak, asym-
metric peak and lack of resolution among the three
drugs. Another major drawback arises throughout
methodology development to acquire resolution be-
tween saxagliptin and sitagliptin since each drug area
unit eluted at the same time from the column. This
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mobile phase in three different ratios as phosphate
buffer pH 4.0: methanol:acetonitrile (40:10:50%v/v),
phosphate buffer pH 4.0: methanol:acetonitrile (60:
10: 30 %v/v). Correspondingly totally different make
of C18 and C8 column as inspire, Xterra, Intersil ODS
etc., were used throughout the method development.
Yet fail to obtain clear results due lack of resolution
among the drugs. The primary target in developing
this stability-indicating RP-HPLC method is to ach-
ieve the resolution among the all the drugs and its
degradation products. A chromatographic separation
of the three drugs was achieved with a Inertsil C18
(4.6  250 mm, 5 mm) analytical column using buffer
potassium dihydrogen phosphate adjusted pH 4 with
orthophosphoric acid: methanol:acetonitrile
(70:10:20%v/v) in isocratic mode at a flow rate of
1 mL/min, column at ambient temperature and
detection of all the drugs were monitored at 215 nm
using a PDA detector.
5.2. Analysis of formulations
Three totally different brands (Istamet, Janumet,
Kombiglyze) were analyzed by this developed tech-
nique and percentage of the assay were calculated.
Results were found within ICH limit and summarized,
in (Table 2).
5.3. Validation of chromatographic systems
5.3.1. Linearity
Linearity was performed at five different concen-
trations for all titled drugs. The described method
shows outstanding linearity over a range of 100, 150,
200, 250, 300 mg/mL for Met, 1,1.5,2,2.5,3.0 for Saxa
and 10, 15, 20, 25, 30 mg/mL for Sita with excellent
correlation coefficient (0.999) [15]. The intercept and
slope values were computed (Fig. 3).Table 2
Analysis of formulation.
Brand Drug* Label claim
mg/tablet
% Label
claim
% R S D
A þ B (A-Istamet,
B-Kombiglyze)
Met 500 99.90 0.1529
Sita 50 100.32 0.1098
Sexa 5 100.85 0.0858
B þ C (C-Janumet,
B-Kombiglyze)
Met 500 98.86 0.0618
Sita 50 98.36 0.1038
Sexa 5 101.83 0.0835
*Mean of six replicates, Met eMetformin, Sita e Sitagliptin, Saxae
Saxagliptin.5.3.2. Recovery study
Recovery study was conducted at three different
levels and mean recovery values for the Met, Saxa and
Sita were found to be 100.34, 99.64 and 99.52%
respectively. The result was shown (Table 3).
5.3.3. Precision
Precision and intermediate precision/ruggedness of
the analyticalmethodwas established for both systemand
method/procedure. The relative standard deviation was
found less than 2. The result was displayed (Table 4).
5.3.4. Specificity
It had been found that chromatogram of the working
placebo solution, not shown any interference at the
retention time of the Met, Saxa and Sita. Consequently,
it can be concluded that main excipients as crystalline
cellulose, hypromellose microcrystalline cellulose,
polyvinylpyrrolidone, sodium lauryl sulfate, and so-
dium stearyl fumarate that were present in the formu-
lations as excipients does not interfere with the
analytical method for the determinations of Met, Saxa
and Sita. The specificity of the method was also
confirmed by forcing degradation study. In peak purity
study with a photo diode detector, purity angle was
lower than the purity threshold for both the analytes
(Figs. 1 and 2).
5.3.5. Limit of detection (LOD) and limit of quantifi-
cation (LOQ)
The limit of detection of the Met, Saxa, Sita 0.03,
0.0017, 0.025 mg/mL and limit of quantification 0.068,
0.013, 0.084 mg/mL respectively indicating out method
was extremely rapid and sensitive.
5.3.6. System suitability study
System suitability was achieved by checking
various parameters and found within the ICH limit.
Robustness study.
It was evident that there was no much deviation in
the robust chromatograms in evaluation with optimized
one. The results were shown in (Table 5).
5.4. Forced degradation study
Degradation studies reveal the specificity of the
developed method in the presence of degradation
products that was carried in bulk and pharmaceutical
dosage form. It was carried out in combination of three
drugs and purity of drug peaks was established by
purity angles. Pharmaceutical dosage forms were
exposed to totally 5 different stress conditions.
Fig. 1. Chromatogram of working blank solution (placebo).
Fig. 2. Overlay chromatogram of standard and formulation.
Fig. 3. Overlay chromatogram of linearity.
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Table 3
Recovery study.
Drug % Conc. (at
specification
level)
Peak area The amount
added (mg)
The amount
found (mg)
% Recovery Mean recovery
Met* 50 4,471,184 5 5.11 98.68% 100.34%
100 8,684,797 10 9.93 99.27%
150 13,322,070 15 15.23 101.52%
Sita* 50 334,999 5 4.91 98.22% 99.52%
100 670,895 10 9.84 98.35%
150 1,043,580 15 15.30 101.99%
Saxa* 50 67,569 5 5.05 101.02 99.64%
100 132,478 10 9.90 99.03
150 198,397 15 14.83 98.88
*Mean of three replicates, Met e Metformin, Sita e Sitagliptin, Saxa e Saxagliptin.
Table 4
Precision study.
Precision Conc. mg/ml Mean peak area % RSD*
Met* Saxa* Sita* Met* Saxa* Sita* Met* Saxa* Sita*
System precision 200 2 20 8,958,905 139,846.2 702,643 0.56 1.56 1.10
Intermediate precision/ruggedness 8,833,003 131,337.2 689,281 0.92 1.75 1.42
Method precision 8,834,002 131,984.2 697,241 0.88 1.62 1.32
Mean average of six determinations, *Mean of six replicates, Met e Metformin, Sita e Sitagliptin, Saxa e Saxagliptin.
% RSD e Percentage relative standard deviation.
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condition
Degradation under acidic and basic condition may
due to catalysis of ionsiable functional group present in
the drug molecule. Two degradants were observed for
basic and one for acidic condition, but not any more
degrading peaks were reported in the retention time of
the Met, Saxa and Sita respectively. In acidic condition
Met degraded slightly higher than basic whereas SaxaTable 5
Robustness study.
Parameters Modifications System suitabil
USP plate coun
Met*
Flow rate 0.8 2912
Optimized 3111
1.2 3104
Mobile phase composition 10% less 3111
Optimized 3111
10% more 2541
Wavelength þ5 nm 2812
Optimized 3111
5 nm 2712
Column temperature þ5 C 2612
Optimized 3111
5 C 2812
*Met e Metformin, Sita e Sitagliptin, Saxa e Saxagliptin.degraded marginally high in basic condition. Sita
degraded nearly 6% in both acidic and basic conditions.
In both case degradation was performed up to 1 h.
5.4.2. Oxidative degradation
Single gradients were observed in the oxidative
degradation study and not any degradant peaks were
reported in the retention time of Met, Saxa and Sita
respectively. Study was carried up to 30 min.ity result
t USP tailing factor
Sita* Saxa* Met* Sita* Saxa*
4341 5212 1.81 1.32 1.09
4598 6322 1.90 1.37 1.12
4341 5212 1.81 1.32 1.09
4341 5212 1.81 1.32 1.09
4598 6322 1.90 1.37 1.12
4489 5178 1.86 1.36 1.11
4581 6006 1.85 1.35 1.08
4598 6322 1.90 1.37 1.12
4482 5745 1.85 1.32 1.09
4374 5645 1.82 1.32 1.10
4598 6322 1.90 1.37 1.12
4684 5247 1.84 1.35 1.12
Table 6
Forced degradation study.
Parameters No of deg Metformin Saxagliptin Sitagliptin
% A* P A* P T* % A* P A* P T* % A* P A* P T*
Acid (heat 60e70 C for 1 h) 1 89.22 0.12 0.26 93.71 0.19 0.32 95.59 0.24 0.48
Base (heat 60e70 C for 1 h) 2 91.16 0.15 0.32 90.81 0.21 0.44 95.74 0.14 0.39
Peroxide (kept for 30 min) 1 85.93 0.13 0.26 83.53 0.18 0.37 92.91 0.21 0.42
Thermal (heat 60e70 C for 1 h) 2 85.12 0.13 0.36 91.59 0.24 0.31 89.25 0.27 0.48
Photolytic (kept for 5 h) 2 85.02 0.12 0.35 91.21 0.23 030 89.10 0.26 0.47
*% A e assay, P A e purity angle, P T e purity threshold, deg e degrandants.
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15%, 6.5% and 9% respectively. Cause high degrada-
tion in peroxide may be due electron transfer mecha-
nism to form reactive cations and anions.
5.4.3. Photolytic and thermal degradation
In photolytic stress conditions, degradation may due
to the photo oxidation by free radical mechanisms
whereas in a thermal it can be explained on the basis ofFig. 4. Chromatogram o
Fig. 5. Chromatogram ofArrhenius equation. Almost 15%, 9% and 10.5% were
degraded for the Met, Saxa and Sita respectively in
above mentioned 2 different stress conditions for a
specified period of time.
The results were summarized in (Table 6). Even if
unidentified peaks were detected in 5 totally different
above mentioned stress condition, not any more
degrading peaks were found near to the retention time
of the Met, Saxa and Sita respectively (Figs. 4e8).f acid degradation.
basic degradation.
Fig. 7. Chromatogram of thermal degradation.
Fig. 8. Chromatogram of photolytic degradation.
Fig. 6. Chromatogram of peroxide degradation.
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48 S.N. Konari, J.T. Jacob / Karbala International Journal of Modern Science 1 (2015) 39e48Therefore Met, Saxa and Sita are prone to the above
stated condition and are too steady in the projected
technique even in stress condition up to a specified
period of time.
5.4.4. Impact of developed technique
Growing demand of DPP-IV product in pharma-
ceutical market, it was absolutely needed to develop
solitary LC technique for the Muticomponent analysis
of Metformin, Saxagliptin and Sitagliptin that was not
developed or reported up to now. Developed Socratic
stability demonstrating technique has numerous upper
hands over current Simultaneous LC technique. As this
specific technique could also be applied for the
multicomponent estimation of Sita, Met and Sexa,
that's gettable in numerous, trade names. Furthermore,
consumption of the mobile phase was very less since
total runtime of chromatogram was 8 min demon-
strating that each of the 3 drugs were eluted among
8 min. Hence the proposed method was cost-effective
and reliable. The limit of detection and limit of
quantification of Met, Saxa and Sita signifying that
technique is extremely fast and sensitive. Moreover,
overlay chromatogram and forced degradation study
indicate that method was very selective (Fig 2).
Additionally a validation study [16,17] for developed
method as per ICH guideline indicate that the method
was highly reproducible, precise, rapid, simple,
economical, sensitive, accurate and specific for multi-
component estimation of the Met, Saxa and Sita in
pharmaceutical combined dosage form.
6. Conclusion
This technique was established to be easy, rapid,
precise, selective, robust and cheap that may be applied
to a distinct commercially out there combos in phar-
maceutical market used for the treatment of type II
diabetes mellitus specifically in Istamet, Janumet and
Kombiglyze as a novel technique while not the in-
terferences of degradants product from the formulation
or further from excipients. The developed methods
were validated as per ICH guideline and stability study
displayed that technique was helpful in monitoring
drug stability and conjointly could also be applied for
routine analysis in research institutions, in bio analyt-
ical Laboratory, in therapeutic drug monitoring for
clinical trials, in quality control division of pharma-
ceutical industries, in official testing laboratories, in
bio-equivalence studies of combos and clinical
pharmacokinetics.References
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